Treatment response to #Bulevirtide is linked to amelioration of #PortalHypertension in patients with chronic #HepatitisD JHEP Reports www.jhep-reports.eu/article/S258...

Loss of Bile Salt Export Pump (Bsep/Abcb11) Ameliorates Toxin-induced Hepatic Fibrosis via Suppression of Hepatocellular Jun Amino-terminal Kinase Signaling and Hepatic Stellate Cell Activation - Cellular and Molecular Gastroenterology and Hepatology www.cmghjournal.org/article/S235...

Loss of Bile Salt Export Pump (Bsep/Abcb11) Ameliorates Toxin-induced Hepatic Fibrosis via Suppression of Hepatocellular Jun Amino-terminal Kinase Signaling and Hepatic Stellate Cell Activation

Loss of Bsep/Abcb11 results in a hydrophilic bile acid (BA) pool consisting of tetrahydroxylated BAs (THBAs) reducing cholestasis-induced liver injury. In this study, we investigated whether loss of B...

cmghjournal.org

#Liver #Cirrhosis #PortalHypertension A recent @meduniwien.ac.at study investigated #cirrhosis pts with variceal bleeding over two 🕐 🕕 🕘 decades: ✅ decreasing rebleeding🩸rates ✅ lower bleeding-related ☠️ mortality in the more recent decade ☺️ 📕 GIE Endoscopy 🔗 www.giejournal.org/article/S001...

Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades

Acute variceal bleeding (AVB), a severe adverse event of portal hypertension, may cause death in patients with cirrhosis. We investigated whether outcomes after AVB have improved over time.

giejournal.org

Pathomechanistic #Phenotypes of #Cirrhosis Dalila Costa🇵🇹 Jonel Trebicka🇩🇪 Cristina Ripoll🇪🇸 Richard Moreau🇫🇷 @rajivjalan.bsky.social🇬🇧 Reiberger🇦🇹 📈 Portal Hypertension #PH & 🔥 Inflammation #SI coexist in pts w/ cirrhosis 💡review on PH-SI interplay in distinct cirrhosis stages @easlnews.bsky.social

Nature Reviews Gastroenterology & Hepatology@natrevgastrohep.nature.com · last yr.

New online! Interaction of inflammation and portal hypertension in cirrhosis progression

Today these two fellows rocked their VENIA DOCENDI 🎓David CHROMY : STIs & #HepatitisC 🎓Mathias JACHS : NITs in #PortalHypertension my personal highlights: @mathiasjachs.bsky.social in @lancetgastrohep.bsky.social Spleen Stiffness 🔗 t.ly/DysXB Chromy in #UEGJ DAAs in acute #HCV 🔗 t.ly/nIZ2a

Our @GeorgKRAMER myself & @CristinaRIPOLL perspective on staging of #Decompensated #Cirrhosis - this was a Letter ✉️ to @jhepatology.bsky.social in response to an article by Dr. Verma @rajivjalan.bsky.social et al #NonAcuteDecompensation (NAD) 🔗 t.ly/mc4VG - who responded w/ an interesting proposal

❓Does #Smoking matter in #Cirrhosis❓ @benedikthofer.bsky.social of @meduniwien.ac.at demonstrates that indeed smoking 📈 triggers 🔥 inflammation & 🩸angiogenesis 🦀 leads to extrahepatic cancer 🦀 and tends to increase risk of #livercancer #HCC 📕 @LiverInt 🔗 t.ly/8Vr-0

Transcriptome analysis shows that 67% (n=13563) of all human proteins (n=20162) are expressed in the liver and 978 of these genes show an elevated expression in the liver compared to other tissue types. Source: www.proteinatlas.org/humanproteom...

🚨 How do ⚡injury mechanisms and 🕑 disease states from health ➡️ fibrosis ➡️ regression shape the NO–sGC–cGMP pathway in chronic #liver #cirrhosis? Check out our comprehensive assessment of regulation patterns of this pivotal pathway here: rdcu.be/exM9Z @reibergerthomas.bsky.social

Molecular patterns of the NO-sGC-cGMP pathway in progressive and regressive liver fibrosis models

Scientific Reports - Molecular patterns of the NO-sGC-cGMP pathway in progressive and regressive liver fibrosis models

rdcu.be

🌍 #WorldHepatitisDay #2025 🇦🇹 contributions to understanding & Elimination of #Hepatitis 1⃣ #HBV-ART in #HIV 🔗 t.ly/6TXxR 2⃣ Curing #HCV in #HIV 🔗 t.ly/FiLPq 3⃣ Eliminate #HCV in 🇦🇹AT 🔗 t.ly/CBw3o 4⃣ Followup after #HCV cure 🔗 t.ly/KvSrs

Chronische #Lebererkrankungen im Fokus: @mathiasjachs.bsky.social​, #ResearcherOfTheMonth der #MedUniWien, hat gezeigt, dass Pfortaderhochdruck schmerzfrei durch Messung der Organsteifigkeit diagnostiziert werden kann. Mehr im Video in gesamter Länge! 🎥➡️ https://bit.ly/3G6VoGC

REMEMBERING PROFESSOR JAUME BOSCH President of Bavneo @bavenocoop.bsky.social Friend and Mentor to many

🖤 With deep sorrow, we announce the passing of Prof. Dr. Jaime Bosch, President of the Baveno Cooperation. A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure. Rest in peace, Jaime

🎂 30Y of .mp3 🎵 created @ Frauenhofer Institute 🔗 t.ly/f6A1t by 🧑‍🎓 Karlheinz Brandenburg 🔗 t.ly/8vojd 🙏 for good vibes when i grew up ♻️ Napster 🔗 t.ly/lqPRP ⏯️ Winamp 🔗 t.ly/_sR05

Drs. @LorenzBALCAR of @meduniwien.ac.at & @MartaTONON identify a #cirrhosis population with #ascites at particular risk for shortterm #PortalHypertension complications @jhepatology.bsky.social Reports: t.ly/iCvXY Ascites #Grade3 + 🚨 MELD ≥12 or 🚨 Na ≤135 ➡️ good candidates for #TIPS

Risk of portal hypertensive complications preventable by TIPS in patients with ascites

Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment of recurrent/refractory ascites in patients with cirrhosis. The aim of this study was to identify patients with ascites a...

t.ly

Drs. @LukasHARTL and @MarleneHINTERSTEININGER of @meduniwien.ac.at showed in @CGH @AGA that adding the #Vasopressin #ADH Biomarker #Copeptin to the MELD score improves prognostication of patients with #cirrhosis #ACLD 📖 the full study 🔗 t.ly/11GOg @easlnews.bsky.social @bavenocoop.bsky.social

🌍⏩ #MedUniVienna ranks 66th in #ClinicalMedicine and is among the top 200 in the US News Global #UniversityRanking. 🔝📌 In the @timeshighered.bsky.social​ Impact Ranking 2025, MedUni Vienna is 10th worldwide in "Good Health and Well-Being". Details ⬇️

US News Ranking: MedUni Vienna among the best medical universities in the world

Read more!

meduniwien.ac.at

The #HEPEX Hepatic Experimental Lab at @meduniwien.ac.at and @cemm.oeaw.ac.at works on Disease-driving #Pathomechanisms in #Liver #Fibrosis & #PortalHypertension 🕸️ #Macrophages in #Fibrosis Resolution 🤖 #MachineLearning & #Pathomics in #LiverHistology 🦠 #Gut-Liver-Axis 🩸 #Anticoagulation

@who.int has set Elimination of 🦠 #ViralHepatitis #B #C as a global goal for 2030 #Prisons remain a Hot ♨️ Spot for #HepC #HCV In Vienna 🇦🇹 we focus on the incarcerated risk population and offer onsite screening and treatment @worldhepalliance.bsky.social @easlnews.bsky.social

We kicked off the week with Roger Kamm (@mitdeptofbe.bsky.social) for a #CeMMinar on brain neurovascular models & its applications to modeling drug & toxin transport. Thanks to Roger for the great insights & hosts @lderooij.bsky.social & @ar-abdelfattah.bsky.social

🇦🇹 Austrian GI/Liver Meeting 2025 3 rising 🌟 stars of our research group #MOTION @crgmotion.bsky.social @meduniwien.ac.at presented posters on hot 🔥 topics in #Hepatology - Clinical Course of #NAD non-acute decompensation - #SpleenStiffness in #PortalHypertension - #Ultrasound Elastography in MASLD

Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades - Gastrointestinal Endoscopy www.giejournal.org/article/S001...

Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades

Acute variceal bleeding (AVB), a severe adverse event of portal hypertension, may cause death in patients with cirrhosis. We investigated whether outcomes after AVB have improved over time.

giejournal.org

📈 Activation of🩸#Vasopressin System in #Cirrhosis tries to compensate for 🫀 #hemodynamic & 💧#sodium #fluid abnormalities Drs. HARTL & HINTERSTEININGER of @meduniwien.ac.at in 🤝with efclif.com show in📕 #CGH 🔗 t.ly/joCs5 ▶️ #Vasopressin biomarker #COPEPTIN predicts #ACLF in cirrhosis

#LiverResearch team #HEPEX-Lab @meduniwien.ac.at is affiliated w Center for Molecular Medicine @cemm.oeaw.ac.at @KatjaSommer #Gut-Liver-Axis @VladTaru #LiverFailure #ACLF @BenHofer #Cirrhosis #Recompensation @KathiBonitz restaurative #Macrophages @ThomasSorz #AI Patho Spatial Transcritomics

CeMM@cemm.oeaw.ac.at · last yr.

🔬 New #EquationsForLife! @reibergerthomas.bsky.social's Group studies #PortalHypertension & uses #OhmsLaw to model blood flow. Their 2024 studies reveal gene expression patterns linked to PH & show it is a key risk factor for complicatoins in #MASLD. 🔎 tinyurl.com/CeMMRR2024-R...

Study by our #Liver #Team @meduniwien.ac.at and @MedHochschuleHannover Minimal residual ascites 3 months after #TIPS implantation implicates worse clinical outcome in patients with #liver #cirrhosis published in @jhepatology.bsky.social #Reports 🔗 sciencedirect.com/science/arti...

Minimal residual ascites 3 months after TIPS implantation implicates worse clinical outcomes in patients with cirrhosis

Transjugular intrahepatic portosystemic shunt (TIPS) implantation is indicated for recurrent/refractory ascites in patients with cirrhosis. The progno…

sciencedirect.com

#LiverSky 📘 JOURNAL OF HEPATOLOGY #JHEPATOL @jhepatology.bsky.social is the flagshipjournal of 🇪🇺 #EASL @easlnews.bsky.social 📈 Impact Factor of 26.8 ➡️ 2.1% 🔝Percentile Consider to submit your #Liver #Research 🔗 www.journal-of-hepatology.eu @heinerwedemeyer.bsky.social @docberza.bsky.social

#LiverSky What is shown here?

🚨 #LiverSky interested in #Cirrhosis and #PortalHypertension ➡️ Read the #Baveno VII Consensus 🔗 t.ly/1P7Ta Get Ready and Register for the #Baveno VIII Consensus 📆 27-28 MARCH 2026 🔗 baveno8.org @bavenocoop.bsky.social @easlnews.bsky.social @aasldnews.bsky.social

⚠️ #Hepatitis B Elimination @easlnews.bsky.social @who.int @lancetgastrohep.bsky.social 😑 73% met #WHO criterion of ≤0.5% HBsAg prevalence 😑 67% have universal #HBV birth vaccinations ☹️ Suboptimal #WHO diagnosis coverage target of 60% 😱 no country met #HBV treatment target

⚠️ #Hepatitis C Elimination @easlnews.bsky.social @who.int @lancetgastrohep.bsky.social 😑 not all countries have national HCV action plans ☹️ 36% have (partial) restrictions on curative #HCV treatments 😑 30% met HCV #WHO diagnosis coverage target of 60% ☹️ only 15% met HCV #WHO treatment target